1. Home
  2. EVTL vs OTLK Comparison

EVTL vs OTLK Comparison

Compare EVTL & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vertical Aerospace Ltd.

EVTL

Vertical Aerospace Ltd.

HOLD

Current Price

$5.33

Market Cap

547.8M

Sector

Industrials

ML Signal

HOLD

Logo Outlook Therapeutics Inc.

OTLK

Outlook Therapeutics Inc.

HOLD

Current Price

$1.59

Market Cap

119.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVTL
OTLK
Founded
2016
2010
Country
United Kingdom
United States
Employees
N/A
17
Industry
Aerospace
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
547.8M
119.6M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
EVTL
OTLK
Price
$5.33
$1.59
Analyst Decision
Strong Buy
Buy
Analyst Count
5
4
Target Price
$13.20
$4.67
AVG Volume (30 Days)
2.4M
3.6M
Earning Date
08-05-2025
12-19-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,413,535.00
Revenue This Year
N/A
$2,048.59
Revenue Next Year
N/A
$142.11
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.76
$0.79
52 Week High
$14.62
$3.39

Technical Indicators

Market Signals
Indicator
EVTL
OTLK
Relative Strength Index (RSI) 49.34 39.72
Support Level $5.21 $1.78
Resistance Level $6.06 $2.03
Average True Range (ATR) 0.37 0.25
MACD -0.09 -0.07
Stochastic Oscillator 25.86 6.39

Price Performance

Historical Comparison
EVTL
OTLK

About EVTL Vertical Aerospace Ltd.

Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a world-wide aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero operating emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Share on Social Networks: